The work by Capello et al.(1) published in this issue of the Journal of Nuclear Medicine
demonstrates an important paradigm shift currently invading investigations and practice in …

Nuclear Medicine, Wild et al. report the binding and animal biodistribution data of [Lys40
(Ahx-DTPA-111In) NH2]-exendin-4 (Ahx is aminohexanoic acid; DTPA is …

Oncogene addiction is an intriguing new term that has emerged in the lexicon of cancer
biology (1). This term implies that tumor cells may have an extraordinary, almost complete …

Peptide receptor radionuclide therapy (PRRT) is highly effective in neuroendocrine tumors
(NET). In the NETTER-1 trial, progression-free survival at month 20 in patients with …

Over the past few years, nuclear medicine has undergone impressive growth with the
development of positron emission tomography (PET), especially using 18F-fluoro-deoxy …

The field of molecular imaging has witnessed tremendous expansion over the last decade
(1). A wide variety of molecular imaging agents (eg, radiolabeled, fluorescently labeled, and …

Purpose: Radionuclide therapy directed against tumors that express somatostatin receptors
(SSTRs) has proven effective for the treatment of advanced, low-to intermediate-grade …

Conclusion The critical choice in molecular targeting is to select a target that will have an
impact on patient management. Given the large number of targets that are often associated …

Knowledge of the molecular profile of a tumor not only guides clinical decisions for optimal
treatment but can be harnessed also to monitor treatment response objectively. In this …

Medicine includes a report of a promising agent for the radiopharmaceutical therapy of
metastatic melanoma (1). The report is provocative for several reasons: it provides a …